

PRESS RELEASE

10 September 2025 09:38:00 CEST

IBT PRESENTED “AVOIDING THE SEVERE CONSEQUENCES OF NEC” AT THE NEC SOCIETY SYMPOSIUM IN CHICAGO

Infant Bacterial Therapeutics AB (IBT) presented clinical outcomes following the administration of IBP-9414, an investigational Live Biotherapeutic Product, to preterm infants.

The oral presentation, delivered by Staffan Strömberg, Chief Executive Officer of IBT, focused on the severe consequences of NEC as reported in *The Connection Study* evaluating IBP#9414 in preterm infants. The analysis showed IBP-9414 effects versus placebo after 14 days of treatment:

- Overall death was 48% lower in the IBP#9414 group
- Investigator-reported death due to gastrointestinal causes was reduced by 61% in the IBP#9414 group
- The number of babies in whom necrotized bowel was observed at surgery was reduced by 71% in the IBP#9414 group

“Too many families have faced devastating outcomes from NEC. The data on IBP#9414 offer hope that we are turning a corner. Our analysis of the effects of IBP-9414 has shown a considerable reduction in death rates in preterm infants, meaning that we could potentially change the standard of care for preterm babies and thereby save thousands of babies.” said Staffan Strömberg, CEO of Infant Bacterial Therapeutics.

Staffan continues: “It was an honor to be invited to present these promising effects at the NEC Society symposium in Chicago. The NEC Society brings together the global community, aiming to reduce the suffering from all the terrible consequences that the disease NEC brings.”

“Families like mine, who carry the lifelong devastation of necrotizing enterocolitis, intimately understand the urgent need to better prevent and treat NEC. I am filled with hope as I witness the promise of science offering protection against NEC so all infants can thrive,” shares **Jennifer Canvasser**, Founder and Executive Director of the NEC Society. “It is an honor and privilege to convene the global NEC community at the NEC Symposium. We are dedicated to integrating science, clinical excellence, and lived experience – and we are deeply grateful for IBT’s dedication to NEC research, bringing us closer to our shared vision of a world without this cruel disease.”

About the NEC Society

The **NEC Society** is a nonprofit organization dedicated to building a world without necrotizing enterocolitis (NEC). Founded by **Jennifer Canvasser** in memory of her son Micah, the NEC Society unites clinicians, researchers, and patient-family leaders to drive collaboration, research, and advocacy. The NEC Society organizes the biennial **NEC Symposium**, the world's largest meeting focused on NEC.

Contacts

Staffan Strömberg, CEO

Maria Ekdahl, CFO

info@ibtherapeutics.com

+46 76 219 37 38

Attachments

[IBT presented "Avoiding the severe consequences of NEC" at the NEC Society Symposium in Chicago](#)